Current and Emerging Pharmacological Therapies for Type 2 Diabetes Mellitus: A Comprehensive Review
Abstract
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterised by insulin resistance, impaired pancreatic beta cell function, dysregulated glucagon secretion, altered incretin activity, increased hepatic glucose production and abnormal renal glucose handling. The growing burden of T2DM and its related cardiovascular, renal and metabolic complications has led to a change in focus from conventional glucose-lowering therapy to pharmacological strategies that address broader metabolic and clinical outcomes. This review provides a comprehensive overview of established and emerging pharmacological approaches for managing T2DM, emphasising their therapeutic targets, mechanisms of action, clinical applications, benefits and limitations. The review discusses established therapies, including metformin, sulfonylureas, meglitinides, thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and insulin, in relation to their roles in contemporary diabetes management. The review also examines combination and fixed-dose therapies, as well as the importance of tailoring treatment to an individual's glycaemic status, body weight, cardiovascular risk, renal function, comorbidities, tolerability and treatment response. Recent therapeutic developments are also explored, including dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, oral and non-peptide GLP-1 receptor agonists, glucagon receptor-targeted approaches, and strategies aimed at β-cell protection and regeneration. The potential of emerging approaches involving stem cell- and gene-based interventions to address the underlying pathophysiology of T2DM is also considered. Overall, the pharmacological management of type 2 diabetes mellitus (T2DM) is evolving towards strategies that are both mechanism-based and patient-centred, integrating glycaemic control with cardiovascular, renal, metabolic and weight-related outcomes. Further investigation of emerging therapies may expand the range of options available for long-term disease management.
Keywords: Type 2 diabetes mellitus, Insulin resistance, β-cell dysfunction, GLP-1 receptor agonists, SGLT2 inhibitors, Emerging therapeutics, β-cell regeneration.
Keywords:
Type 2 diabetes mellitus, Insulin resistance, β-cell dysfunction, GLP-1 receptor agonists, SGLT2 inhibitors, Emerging therapeutics, β-cell regenerationDOI
https://doi.org/10.22270/jddt.v16i11.8068References
1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. https://doi.org/10.1038/nrendo.2017.151 PMid:29219149
2. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. Diabetes Res Clin Pract. 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843 PMid:31518657
3. Hills AP, Arena R, Khunti K, et al. Epidemiology and determinants of type 2 diabetes in South Asia. Lancet Diabetes Endocrinol. 2018;6(12):966-978. DOI:10.1016/S2213-8587(18)30204-3 https://doi.org/10.1016/S2213-8587(18)30204-3 PMid:30287102
4. Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400(10365):1803-1820. https://doi.org/10.1016/S0140-6736(22)01655-5 PMid:36332637
5. Usman MS, Khan MS, Butler J. The interplay between diabetes, cardiovascular disease, and kidney disease. In: Chronic Kidney Disease and Type 2 Diabetes. 2021:13-18. https://doi.org/10.2337/db20211-13 PMid:34279879
6. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. https://doi.org/10.3390/ijms21176275 PMid:32872570
7. Guo H, Pan L, Wu Q, et al. Type 2 diabetes and the multifaceted gut-X axes. Nutrients. 2025;17(16):2708. https://doi.org/10.3390/nu17162708 PMid:40871736 PMCid:PMC12389143
8. Khin PP, Lee JH, Jun HS. Pancreatic beta-cell dysfunction in type 2 diabetes. European Journal of Inflammation. 2023 Jan 20;21:1721727X231154152. https://doi.org/10.1177/1721727X231154152
9. Prentki M, Peyot ML, Masiello P, Madiraju SM. Nutrient-induced metabolic stress, adaptation, detoxification, and toxicity in the pancreatic β-cell. Diabetes. 2020 Mar 1;69(3):279-90. https://doi.org/10.2337/dbi19-0014 PMid:32079704
10. Bizzotto R, Jennison C, Jones AG, Kurbasic A, Tura A, Kennedy G, et al. Processes underlying glycemic deterioration in type 2 diabetes: an IMI DIRECT study. Diabetes Care. 2021;44(2):511-518. https://doi.org/10.2337/dc20-1567 PMid:33323478
11. Hulett NA, Scalzo RL, Reusch JE. Glucose uptake by skeletal muscle within the contexts of type 2 diabetes and exercise: an integrated approach. Nutrients. 2022;14(3):647. https://doi.org/10.3390/nu14030647 PMid:35277006 PMCid:PMC8839578
12. Saadati S, Godini R, Reddy A, Teede H, Mousa A. Metabolic crossroads in insulin resistance: exploring lipid dysregulation and inflammation. Front Immunol. 2025;16:1692742. https://doi.org/10.3389/fimmu.2025.1692742 PMid:41376626 PMCid:PMC12685932
13. Engin AB. Mechanism of obesity-related lipotoxicity and clinical perspective. In: Obesity and Lipotoxicity. 2024;1460:131-166. https://doi.org/10.1007/978-3-031-63657-8_5 PMid:39287851
14. Dimitriadis GD, Maratou E, Kountouri A, Board M, Lambadiari V. Regulation of postabsorptive and postprandial glucose metabolism by insulin-dependent and insulin-independent mechanisms: an integrative approach. Nutrients. 2021;13(1):159. https://doi.org/10.3390/nu13010159 PMid:33419065
15. Rabbani N, Thornalley PJ. Unraveling the impaired incretin effect in obesity and type 2 diabetes: key role of hyperglycemia-induced unscheduled glycolysis and glycolytic overload. Diabetes Res Clin Pract. 2024;217:111905. https://doi.org/10.1016/j.diabres.2024.111905 PMid:39447679
16. Caruso I, Marrano N, Biondi G, Genchi VA, D’Oria R, Sorice GP, et al. Glucagon in type 2 diabetes: friend or foe? Diabetes Metab Res Rev. 2023;39(3):e3609. https://doi.org/10.1002/dmrr.3609 PMid:36637256
17. Holst JJ, Gasbjerg LS, Rosenkilde MM. The role of incretins on insulin function and glucose homeostasis. Endocrinology. 2021;162(7):bqab065. https://doi.org/10.1210/endocr/bqab065 PMid:33782700 PMCid:PMC8168943
18. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5-21. https://doi.org/10.1111/dom.13129 PMid:29364588
19. Vallon V. Glucose transporters in the kidney in health and disease. Pflugers Arch. 2020;472(9):1345-1370. https://doi.org/10.1007/s00424-020-02361-w PMid:32144488 PMCid:PMC7483786
20. Zhao L, Yuan J, Yang Q, Ma J, Yang F, Zou Y, et al. Diabetes and its complications: molecular mechanisms, prevention and treatment. Signal Transduct Target Ther. 2026;11(1):22. https://doi.org/10.1038/s41392-025-02401-w PMid:41549124 PMCid:PMC12812840
21. Jacob S, Krentz AJ, Deanfield J, Rydén L. Evolution of type 2 diabetes management from a glucocentric approach to cardio-renal risk reduction: the new paradigm of care. Drugs. 2021;81(12):1373-1379. https://doi.org/10.1007/s40265-021-01554-6 PMid:34302636
22. Haq FU, Siraj A, Ameer MA, Hamid T, Rahman M, Khan S, et al. Comparative review of drugs used in diabetes mellitus-new and old. J Diabetes Mellitus. 2021;11(4):115-131. https://doi.org/10.4236/jdm.2021.114009
23. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, et al. Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions. Circulation. 2020;141(10):843-862. https://doi.org/10.1161/CIRCULATIONAHA.119.041022 PMid:31992065
24. Lee YH, Lim S, Davies MJ. Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors. Nat Rev Endocrinol. 2025;21(12):783-798. https://doi.org/10.1038/s41574-025-01170-4 PMid:40935880
25. Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, et al. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther. 2024;9(1):262. https://doi.org/10.1038/s41392-024-01951-9 PMid:39353925
26. Młynarska E, Czarnik W, Dzieża N, Jędraszak W, Majchrowicz G, Prusinowski F, et al. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci. 2025;26(3):1094. https://doi.org/10.3390/ijms26031094 PMid:39940862 PMCid:PMC11817707
27. Liu H, Wang S, Wang J, Guo X, Song Y, Fu K, et al. Energy metabolism in health and diseases. Signal Transduct Target Ther. 2025;10(1):69. https://doi.org/10.1038/s41392-025-02141-x PMid:39966374 PMCid:PMC11836267
28. Evgenii G, Alexey S, Yulia Z. Insulin resistance and inflammation. Int J Mol Sci. 2026;27(3):1237. https://doi.org/10.3390/ijms27031237 PMid:41683662 PMCid:PMC12898699
29. Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, et al. Metformin: a review of potential mechanism and therapeutic utility beyond diabetes. Drug Des Devel Ther. 2023;17:1907-1932. https://doi.org/10.2147/DDDT.S409373 PMid:37397787 PMCid:PMC10312383
30. Esser N, Utzschneider KM, Kahn SE. Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia. 2020;63(10):2007-2021. https://doi.org/10.1007/s00125-020-05245-x PMid:32894311 PMCid:PMC7476241
31. Lee AA, Khotina VA, Kashirskikh DA, Voronko OE, Gasanov VA, Vasiliev AV. Incretin-based therapies through the decades: molecular innovations and clinical impact. Med Sci (Basel). 2025;13(4):269. https://doi.org/10.3390/medsci13040269 PMid:41283270 PMCid:PMC12641833
32. Liang J, Chen X, Chu Y, Leng Y. The gut-adipose/pancreas axis: a novel perspective on glycolipid metabolism dysregulation in MAFLD and T2DM pathogenesis. Front Endocrinol. 2025;16:1664233. https://doi.org/10.3389/fendo.2025.1664233 PMid:41244044
33. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292. https://doi.org/10.3389/fendo.2024.1431292 PMid:39114288 PMCid:PMC11304055
34. Gronda E, Jessup M, Iacoviello M, Palazzuoli A, Napoli C. Glucose metabolism in the kidney: neurohormonal activation and heart failure development. J Am Heart Assoc. 2020;9(23):e018889. https://doi.org/10.1161/JAHA.120.018889 PMid:33190567 PMCid:PMC7763788
35. Preda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120(5):443-460. https://doi.org/10.1093/cvr/cvae047 PMid:38456601 PMCid:PMC12001887
36. Barroso E, Jurado-Aguilar J, Wahli W, Palomer X, Vázquez-Carrera M. Increased hepatic gluconeogenesis and type 2 diabetes mellitus. Trends Endocrinol Metab. 2024;35(12):1062-1077. https://doi.org/10.1016/j.tem.2024.05.006 PMid:38816269
37. Cheng H, Gang X, Liu Y, Wang G, Zhao X, Wang G. Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes. Am J Physiol Endocrinol Metab. 2020;318(5):E750-E764. https://doi.org/10.1152/ajpendo.00179.2019 PMid:31714795
38. Scoditti E, Sabatini S, Carli F, Gastaldelli A. Hepatic glucose metabolism in the steatotic liver. Nat Rev Gastroenterol Hepatol. 2024;21(5):319-334. https://doi.org/10.1038/s41575-023-00888-8 PMid:38308003
39. Alharbi AG. GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity. Saudi Pharm J. 2025;33(5):34. https://doi.org/10.1007/s44446-025-00038-y PMid:40991062 PMCid:PMC12460220
40. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31-55. https://doi.org/10.1016/j.immuni.2021.12.013 PMid:35021057
41. An Y, Xu BT, Wan SR, Ma XM, Long Y, Xu Y, Jiang ZZ. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. Cardiovasc Diabetol. 2023;22(1):237. https://doi.org/10.1186/s12933-023-01965-7 PMid:37660030 PMCid:PMC10475205
42. Davies MJ, Lim S, Slater T, Goldney J, Philis-Tsimikas A, Franco DR, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2026;12(1):13. https://doi.org/10.1038/s41572-026-00687-w PMid:41857071
43. Martirosyan D, Santrosyan G, McCarthy J, Nguyen A. Metformin: Optimal dosage, interactions, and efficacy. Exploring natural alternatives for diabetes management. Bioact Compd Health Dis. 2025;8(5):177-203. https://doi.org/10.31989/bchd.v8i5.1624
44. Montgomery MK, Bayliss J, Devereux C, Bezawork-Geleta A, Roberts D, Huang C, et al. SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control. Sci Transl Med. 2020;12(559):eaaz8048. https://doi.org/10.1126/scitranslmed.aaz8048 PMid:32878981
45. Weinberg Sibony R, Segev O, Dor S, Raz I. Drug therapies for diabetes. Int J Mol Sci. 2023;24(24):17147. https://doi.org/10.3390/ijms242417147 PMid:38138975 PMCid:PMC10742594
46. Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity: beyond “calories in, calories out”. JAMA Intern Med. 2018;178(8):1098-1103. https://doi.org/10.1001/jamainternmed.2018.2933 PMid:29971406 PMCid:PMC6082688
47. Feingold KR. Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2024.
48. Yong J, Johnson JD, Arvan P, Han J, Kaufman RJ. Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus. Nat Rev Endocrinol. 2021;17(8):455-467. https://doi.org/10.1038/s41574-021-00510-4 PMid:34163039 PMCid:PMC8765009
49. Bou Matar D, Zhra M, Nassar WK, Altemyatt H, Naureen A, Abotouk N, et al. Adipose tissue dysfunction disrupts metabolic homeostasis: mechanisms linking fat dysregulation to disease. Front Endocrinol. 2025;16:1592683. https://doi.org/10.3389/fendo.2025.1592683 PMid:40630101 PMCid:PMC12234313
50. Hedrington MS, Davis SN. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. Expert Opin Pharmacother. 2019;20(18):2229-2235. https://doi.org/10.1080/14656566.2019.1672660 PMid:31593486
51. Zhang K, Dong R, Hu X, Ren C, Li Y. Oat-based foods: chemical constituents, glycemic index, and the effect of processing. Foods. 2021;10(6):1304. https://doi.org/10.3390/foods10061304 PMid:34200160 PMCid:PMC8229445
52. Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM-hype or hope? An analysis based on the current literature. Front Mol Biosci. 2023;10:1130625. https://doi.org/10.3389/fmolb.2023.1130625 PMid:37287751 PMCid:PMC10242023
53. Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44-58. https://doi.org/10.1007/s12325-018-0824-8 PMid:30465123 PMCid:PMC6318231
54. Palmer BF, Clegg DJ. Kidney-protective effects of SGLT2 inhibitors. Clin J Am Soc Nephrol. 2023;18(2):279-289. https://doi.org/10.2215/CJN.09380822 PMid:36220189 PMCid:PMC10103214
55. Mariam Z, Niazi SK. Glucagon-like peptide agonists: a prospective review. Endocrinol Diabetes Metab. 2024;7(1):e462. https://doi.org/10.1002/edm2.462 PMid:38093651 PMCid:PMC10782143
56. Batista TM, Haider N, Kahn CR. Defining the underlying defect in insulin action in type 2 diabetes. Diabetologia. 2021;64(5):994-1006. https://doi.org/10.1007/s00125-021-05415-5 PMid:33730188
57. Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. Cell. 2022;185(3):419-446. https://doi.org/10.1016/j.cell.2021.12.016 PMid:35120662 PMCid:PMC11152570
58. Johanns M, Hue L, Rider MH. AMPK inhibits liver gluconeogenesis: fact or fiction? Biochem J. 2023;480(1):105-125. https://doi.org/10.1042/BCJ20220582 PMid:36637190
59. Clapham JC. Sixty years of drug discovery for type 2 diabetes: where are we now? In: Type 2 Diabetes: Methods and Protocols. 2020;2076:1-30. https://doi.org/10.1007/978-1-4939-9882-1_1 PMid:31586319
60. Han G, Chen R, Wang P, et al. Multi-target hypoglycemic agents in glucose metabolism disorders and neurodegenerative diseases. J Transl Med. 2026. https://doi.org/10.1186/s12967-026-08878-5
61. Lau HH, Gan SU, Lickert H, Shapiro AM, Lee KO, Teo AK. Charting the next century of insulin replacement with cell and gene therapies. Med. 2021;2(10):1138-1162. https://doi.org/10.1016/j.medj.2021.09.001 PMid:35590204
62. Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing fixed-ratio combination therapy in type 2 diabetes. Adv Ther. 2019;36(2):265-277. https://doi.org/10.1007/s12325-018-0868-9 PMid:30610613 PMCid:PMC6824345
63. Steulet A, Obura B, Waitt C, Laker E, Nicol MR, Cresswell FV. Clinical pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to sub-Saharan Africa. Br J Clin Pharmacol. 2024;90(9):2079-2091. https://doi.org/10.1111/bcp.16154 PMid:38923554
64. Kim DW, Weon KY. Pharmaceutical application and development of fixed-dose combination: dosage form review. J Pharm Investig. 2021;51(5):555-570. https://doi.org/10.1007/s40005-021-00543-x
65. Wilkins CA, Hamman H, Hamman JH, Steenekamp JH. Fixed-dose combination formulations in solid oral drug therapy: advantages, limitations, and design features. Pharmaceutics. 2024;16(2):178. https://doi.org/10.3390/pharmaceutics16020178 PMid:38399239 PMCid:PMC10892518
66. Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(5):370-381. https://doi.org/10.1016/S2213-8587(18)30023-8 PMid:29483060
67. Harris SB, Cheng AYM, Davies MJ, Gerstein HC, Green JB, Skolnik N. Person-centered, outcomes-driven treatment: a new paradigm for type 2 diabetes in primary care. ADA Clinical Compendia. 2020;2020(2). https://doi.org/10.2337/db2020-02 PMid:32667763
68. Meng L, Li Z, Xu L, Wei F, Ji H, Zhang L, Zhu A, Zhou Z. Emerging technologies for early risk stratification and precision management of diabetic kidney disease: a multimodal framework integrating digital phenotypes and clinical biomarkers. Front Endocrinol. 2026;16:1728293. https://doi.org/10.3389/fendo.2025.1728293 PMid:41585789 PMCid:PMC12827177
69. Cabré F, Centelles JJ, Cascante M. From current therapeutics to multitarget ligands: a review of diabetes pharmacological treatments. Pharmaceutics. 2025;17(9):1125. https://doi.org/10.3390/pharmaceutics17091125 PMid:41012462 PMCid:PMC12473160
70. Podder D, Stala O, Miah A, Agyapong A, Moore ME, Hirani R, et al. Incretin-based multi-agonist therapies for type 2 diabetes mellitus and obesity: mechanisms, clinical efficacy, and future directions. Diabetology. 2026;7(3):46. https://doi.org/10.3390/diabetology7030046
71. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Landó LF, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736(21)01324-6 PMid:34186022
72. Khan I, Meenakshi S, Abubakar M, Kumar N, Gaikwad VL, Rai A, Murti K. Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation. Endocrine. 2026;91(1):216. https://doi.org/10.1007/s12020-026-04686-5 PMid:42387035
73. Rabbani SA, Saini M, El-Tanani M, Kumar R, Matalka I, El-Tanani Y, et al. Oral GLP-1-based therapeutics in the obesity-metabolic syndrome-diabetes continuum: translational advances, clinical barriers, and emerging strategies. Pharmaceuticals. 2026;19(5):732. https://doi.org/10.3390/ph19050732 PMid:42198407 PMCid:PMC13209388
74. Iriarte-Mesa C, Juère E, Bileck A, Kremsmayr T, Goodson ML, Ehrlich A, et al. Mesoporous silica nanoparticles-based formulations for enhanced oral delivery of peptide drugs: a case study on insulin. Small. 2026;22(24):e13347. https://doi.org/10.1002/smll.202513347 PMid:41866874 PMCid:PMC13114519
75. Petersen J, Finan B, Johansen VBI, Müller TD, Clemmensen C. The evolving landscape of obesity pharmacotherapy. Nat Rev Drug Discov. 2026;25(8):619-647. https://doi.org/10.1038/s41573-026-01427-1 PMid:42129460
76. Zeigerer A, Sekar R, Kleinert M, Nason S, Habegger KM, Müller TD. Glucagon’s metabolic action in health and disease. Compr Physiol. 2021;11(2):1759-1783. https://doi.org/10.1002/j.2040-4603.2021.tb00161.x PMid:33792899 PMCid:PMC8513137
77. Neff GW. Shared mechanistic pathways of glucagon signalling: unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions. Diabetes Obes Metab. 2025;27(12):6869-6883. https://doi.org/10.1111/dom.70148 PMid:41025406
78. von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M. Current and future therapies for type 1 diabetes. Diabetologia. 2021;64(5):1037-1048. https://doi.org/10.1007/s00125-021-05398-3 PMid:33595677
79. Bourgeois S, Coenen S, Degroote L, Willems L, Van Mulders A, Pierreux J, et al. Harnessing beta cell regeneration biology for diabetes therapy. Trends Endocrinol Metab. 2024;35(11):951-966. https://doi.org/10.1016/j.tem.2024.03.006 PMid:38644094
80. Slaninova V, Pavlinkova G. Stem cell-derived islet replacement therapies for diabetes: current progress and translational challenges. Mol Med. 2026. https://doi.org/10.1186/s10020-026-01610-5
81. Pei X, Huang D, Li Z. Genetic insights and emerging therapeutics in diabetic retinopathy: from molecular pathways to personalized medicine. Front Genet. 2024;15:1416924. https://doi.org/10.3389/fgene.2024.1416924 PMid:39246572 PMCid:PMC11378321
82. Sugandh FN, Chandio M, Raveena FN, Kumar L, Karishma FN, Khuwaja S, et al. Advances in the management of diabetes mellitus: a focus on personalized medicine. Cureus. 2023;15(8):e43697. https://doi.org/10.7759/cureus.43697
83. Fernando K, Bain SC, Holmes P, Jones PN, Patel DC. Glucagon-like peptide 1 receptor agonist usage in type 2 diabetes in primary care for the UK and beyond: a narrative review. Diabetes Ther. 2021;12(9):2267-2288. https://doi.org/10.1007/s13300-021-01116-9 PMid:34309808 PMCid:PMC8312211
84. Wolff J, Hefner G, Normann C, Kaier K, Binder H, Hiemke C, et al. Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry. Pharmacoepidemiol Drug Saf. 2021;30(9):1258-1268. https://doi.org/10.1002/pds.5310 PMid:34146372
85. Home PD. An overview of insulin therapy for the non-specialist. Diabetes Obes Metab. 2025;27(Suppl 5):3-15. https://doi.org/10.1111/dom.16280 PMid:40035222 PMCid:PMC12169081
86. Wiles K, Chappell L, Clark K, Elman L, Hall M, Lightstone L, et al. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol. 2019;20(1):401. https://doi.org/10.1186/s12882-019-1560-2 PMid:31672135
87. Richardson K, Kiptoo J, Mpora Odongkara B, Ojara FW, Waitt C. Maternal-to-infant transfer of medications for type 2 diabetes mellitus via breastmilk: a systematic review of available evidence and clinical guidelines. Clin Pharmacol Ther. 2026;119(5):1223-1234. https://doi.org/10.1002/cpt.70211 PMid:41670332 PMCid:PMC13083373
88. Cabré A, Galiero R, Rocco M, Tagliaferri G, Piacevole A, Nilo D, et al. Modern challenges in type 2 diabetes: balancing new medications with multifactorial care. Biomedicines. 2024;12(9):2039. https://doi.org/10.3390/biomedicines12092039 PMid:39335551
89. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9):e722-e759. https://doi.org/10.1161/CIR.0000000000001040
90. Zafer M, Tavaglione F, Romero-Gómez M, Loomba R. GLP-1 receptor agonists and glucagon/GIP/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD. Aliment Pharmacol Ther. 2025;61(12):1872-1888. https://doi.org/10.1111/apt.70196 PMid:40364529 PMCid:PMC12323726
91. Movahednasab M, Dianat-Moghadam H, Khodadad S, Nedaeinia R, Safabakhsh S, Ferns G, et al. GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation. Diabetol Metab Syndr. 2025;17(1):60. https://doi.org/10.1186/s13098-025-01623-w PMid:39962520 PMCid:PMC11834518
92. Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol. 2020;11:178. https://doi.org/10.3389/fendo.2020.00178 PMid:32308645 PMCid:PMC7145895
93. Khachaturov M, Goulis DG. Beyond GLP-1 monotherapy: novel multi-agonists, amylin analogues, and combination strategies in obesity and type 2 diabetes. Diabetes Obes Metab. 2026;28(7):5556-5589. https://doi.org/10.1111/dom.70822 PMid:42098899
94. Aktas G. A scoping review on recent advances in antidiabetic medications: from GLP-1 receptor agonists to dual and triple agonists. Adv Clin Pharmacol Ther. 2025;2(2):47-57. https://doi.org/10.63623/8cv4gh26
95. Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24(8):631-650. https://doi.org/10.1038/s41573-025-01183-8 PMid:40281304 PMCid:PMC13711496
96. Weiskirchen R, Lonardo A. Semaglutide from bench to bedside: the experimental journey towards a transformative therapy for diabetes, obesity and metabolic liver disorders. Med Sci (Basel). 2025;13(4):265. https://doi.org/10.3390/medsci13040265 PMid:41283266 PMCid:PMC12642005
Published
Abstract Display: 0
PDF Downloads: 0
PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Dheeya Patel , Nikita Patel , Renu Das , Chandan Kumar

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

.